• Steris’ FY27 second-quarter diluted earnings rose 13% year over year to $2.19 per share.
• Revenue climbed 9% to $1.6 billion, while Life Sciences revenue jumped 18% to $170.6 million.
• Quarterly reported results included an approximately $20 million pretax benefit from tariff refunds.
• A new restructuring plan targets approximately $9 million in annualized savings and carries approximately $45 million in total charges.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Steris plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-070220), on November 04, 2026, and is solely responsible for the information contained therein.